Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
09:31am, Friday, 02'nd Feb 2024
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
3 Top Pharma Stocks to Buy Now: February 2024
05:00pm, Thursday, 01'st Feb 2024
Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.
Exploring Analyst Estimates for Gilead (GILD) Q4 Earnings, Beyond Revenue and EPS
10:21am, Thursday, 01'st Feb 2024
Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
3 Top Value Stocks to Buy and Hold for 2024
11:30am, Tuesday, 30'th Jan 2024
These high-quality companies are solid—and their stocks look cheap.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
11:07am, Tuesday, 30'th Jan 2024
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus rises, Gilead slips on expanded agreement
09:53am, Tuesday, 30'th Jan 2024
Shares in Arcus Biosciences Inc rose after Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) agreed to invest another $320 million as part of a tweaked collaboration agreement. Extending a multiple-drug pa
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
06:56pm, Monday, 29'th Jan 2024
Gilead Sciences (GILD) reachead $79.07 at the closing of the latest trading day, reflecting a -0.57% change compared to its last close.
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
06:20pm, Monday, 29'th Jan 2024
Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer
Embracing The Mania And Yield At A Reasonable Price
07:30am, Monday, 29'th Jan 2024
Embracing The Mania And Yield At A Reasonable Price
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
07:06pm, Tuesday, 23'rd Jan 2024
Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
12:40pm, Tuesday, 23'rd Jan 2024
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
09:10am, Tuesday, 23'rd Jan 2024
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
Why Gilead Sciences Stock Got Mashed on Monday
06:08pm, Monday, 22'nd Jan 2024
Trodelvy did not perform well in an important clinical trial. Management is vowing to keep seeking other patient populations to treat with the drug.
Three-Stock Lunch: Affirm Holdings, Gilead Sciences and 3M
03:30pm, Monday, 22'nd Jan 2024
George Ball, chairman at Sanders Morris Harris, joins 'Power Lunch' to discuss Ball's investment take on three stocks: Affirm Holdings, Gilead Sciences, and 3M.
Gilead shares plunge on lung cancer trial disappointment
12:19pm, Monday, 22'nd Jan 2024
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in the overall
